



N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 18, 2014, Rodney S. Markin, M.D., Ph.D. notified Transgenomic, Inc. (the “Company”) of his decision to resign from the Board of Directors (the “Board”) of the Company, including from his position as Chairman of the Board, and from all committee memberships, effective as of December 31, 2014. Dr. Markin’s decision to resign from the Board was for personal reasons and was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRANSGENOMIC,  
INC.

December 23, 2014 By/s/ Paul Kinnon  
Paul Kinnon  
President and  
Chief Executive  
Officer